Cigna Group Valuation
Is CI * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of CI * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: CI * (MX$5929) is trading below our estimate of fair value (MX$16537.57)
Significantly Below Fair Value: CI * is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CI *?
Other financial metrics that can be useful for relative valuation.
What is CI *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$100.54b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 0.6x |
Enterprise Value/EBITDA | 11.6x |
PEG Ratio | 2x |
Price to Earnings Ratio vs Peers
How does CI *'s PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 29.4x | ||
CVS CVS Health | 10.1x | 6.9% | US$84.7b |
FRE Fresenius SE KGaA | 43.4x | 22.6% | €15.3b |
LH Laboratory Corporation of America Holdings | 41.9x | 21.0% | US$16.7b |
FME Fresenius Medical Care | 22x | 20.7% | €11.0b |
CI * Cigna Group | 19.5x | 9.6% | Mex$100.5b |
Price-To-Earnings vs Peers: CI * is good value based on its Price-To-Earnings Ratio (19.5x) compared to the peer average (29.4x).
Price to Earnings Ratio vs Industry
How does CI *'s PE Ratio compare vs other companies in the Global Healthcare Industry?
Price-To-Earnings vs Industry: CI * is good value based on its Price-To-Earnings Ratio (19.5x) compared to the Global Healthcare industry average (21.4x).
Price to Earnings Ratio vs Fair Ratio
What is CI *'s PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 19.5x |
Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate CI *'s Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.